Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 20th Preview)
-
FDA approval for first-in-class gene therapy in Sanfilippo A
The FDA has approved Ultragenyx’s one-time gene therapy rebisufligene etisparvovec (Fayuvi) for Sanfilippo syndrome type A (MPS IIIA), the first FDA-approved treatment for the underlying cause of the rare neurodegenerative disorder. The approval marks a turnaround after the agency previously rejected the application over manufacturing concerns. Fayuvi is delivered as a single-dose adeno-associated virus (AAV) vector therapy intended to restore SGSH gene function. In Sanfilippo syndrome, loss-of-function variants in SGSH lead to toxic buildup of partially degraded heparan sulfate in the lysosome, driving progressive loss of speech, vision, and mobility and shortened survival. Ultragenyx’s treatment is positioned as a potential disease-modifying option for a condition that historically had no approved therapies to alter course. The FDA cited the therapy’s promise for rare pediatric diseases, while patient groups noted both relief and continued variability in expected response. In 2025, the FDA denied approval during an application cycle when Fayuvi was being studied in Phase II/III trials (NCT02716246), underscoring that quality and manufacturing controls were central to the regulatory path.
-
FDA lifts lid on Lilly’s oral SERD combination for breast cancer
Eli Lilly’s oral selective estrogen receptor degrader (SERD) Inluriyo has won FDA approval in combination for certain patients with metastatic breast cancer as a second-line regimen. The approval expands the SERD portfolio with an all-oral approach aimed at established standards of care. The regimen is specifically for patients whose disease meets the trial-defined criteria for second-line treatment. Lilly’s authorization adds incremental options for clinicians seeking endocrine-therapy strategies that bypass estrogen receptor signaling through targeted degradation. For investors and competitors, the update strengthens Lilly’s position in hormone-driven oncology and keeps pressure on rival SERD programs and sequencing strategies. It also reinforces the company’s broader push in oral, combination endocrine regimens. Regulatory approvals of oncology combinations tend to accelerate adoption quickly when safety profiles and endpoints are clear in registrational studies, though the label specifics determine the speed of uptake.
-
EMA CHMP recommends multiple therapies including hemophilia A preventive and ovarian cancer
The European Medicines Agency’s CHMP has recommended approving Novo Nordisk’s hemophilia A preventive drug, alongside positive opinions for seven other medicines and 11 label expansions. The CHMP’s package covers both new therapies and updates to existing products, moving the medicines closer to final EU authorization. Among the recommendations highlighted in the CHMP list are two new ovarian cancer therapies and what is described as a potential first oral treatment option for hidradenitis suppurativa. The month’s slate also includes additional medicines across other therapeutic areas. CHMP recommendations do not represent the final EU step, but they are a key milestone that typically precedes European Commission approval. For biotech and pharma, the decision can quickly reshape competitive positioning around access and treatment guidelines. Label expansions matter for companies because they often broaden eligible patient populations or add new indications, potentially expanding prescribing and revenue opportunity well beyond the initial approval scope.
-
Ultragenyx clears a regulatory hurdle for MPS IIIA after prior FDA denial
Separate from the headline approval coverage, the approval narrative reflects the tight link between FDA scrutiny and manufacturing quality for gene therapies. The Fayuvi decision follows a prior FDA refusal, in which the agency pointed to concerns about Ultragenyx’s manufacturing process for the AAV-based product. That earlier setback is notable for gene therapy developers: even when clinical data are strong, regulatory review can hinge on process controls, product consistency, and the ability to reliably manufacture across commercial timelines. The new approval closes a four-year gap since the company’s earlier application and puts Ultragenyx at the center of the rare-disease gene therapy market with a first-of-its-kind indication in MPS IIIA. Clinicians and payers will now focus on real-world implementation questions, including patient selection, durability of expression, and outcomes across the labeled population.
-
Lilly’s brenipatide posts early Phase I dose-selection data for CNS and addiction-adjacent disorders
Eli Lilly presented early clinical data for brenipatide, its once-weekly GIP/GLP-1 receptor agonist candidate designed to engage central nervous system and inflammatory pathways tied to reward and addiction biology. At Psych Congress 2026 in New Orleans, Lilly reported dose-selection support from a Phase I study (J2S-MC-GZMD; NCT06606106). In the poster, Lilly described brenipatide pharmacokinetics consistent with a durability of exposure that extends beyond weekly dosing—an attribute the company said it is testing in the neuroscience space. Reported mean half-life ranged from 9.08 to 12.5 days, with longer half-life in higher-dose cohorts. Lilly’s Phase III plans laid out in the presentation include evaluation of brenipatide in major depressive disorder (MDD) and alcohol use disorder (AUD), extending the company’s GLP-1–derived platform into psychiatric and substance-use targets. For the field, the program is notable because it reframes the obesity-and-diabetes franchise chemistry toward neuroinflammatory and reward-circuit hypotheses, setting up a head-to-head competitive challenge with other CNS-directed metabolic agents.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.